NDC 0169-2800

Saxenda

Liraglutide

Saxenda is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Liraglutide.

Product ID0169-2800_22354b1e-31ba-4cad-974e-3620604d2f6d
NDC0169-2800
Product TypeHuman Prescription Drug
Proprietary NameSaxenda
Generic NameLiraglutide
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2014-12-31
Marketing CategoryNDA / NDA
Application NumberNDA206321
Labeler NameNovo Nordisk
Substance NameLIRAGLUTIDE
Active Ingredient Strength6 mg/mL
Pharm ClassesGLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [CS],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 0169-2800-15

5 SYRINGE, PLASTIC in 1 CARTON (0169-2800-15) > 3 mL in 1 SYRINGE, PLASTIC
Marketing Start Date2015-01-19
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0169-2800-15 [00169280015]

Saxenda INJECTION, SOLUTION
Marketing CategoryNDA
Application NumberNDA206321
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2015-01-19

NDC 0169-2800-97 [00169280097]

Saxenda INJECTION, SOLUTION
Marketing CategoryNDA
Application NumberNDA206321
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2015-01-19

NDC 0169-2800-90 [00169280090]

Saxenda INJECTION, SOLUTION
Marketing CategoryNDA
Application NumberNDA206321
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2015-01-19

Drug Details

Active Ingredients

IngredientStrength
LIRAGLUTIDE6 mg/mL

OpenFDA Data

SPL SET ID:3946d389-0926-4f77-a708-0acb8153b143
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1598268
  • 897122
  • Pharmacological Class

    • GLP-1 Receptor Agonist [EPC]
    • Glucagon-Like Peptide 1 [CS]
    • Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]

    NDC Crossover Matching brand name "Saxenda" or generic name "Liraglutide"

    NDCBrand NameGeneric Name
    0169-2800Saxendaliraglutide
    50090-4257Saxendaliraglutide
    0169-4060Victozaliraglutide
    50090-2853Victozaliraglutide
    50090-4503Victozaliraglutide

    Trademark Results [Saxenda]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    SAXENDA
    SAXENDA
    79141628 4541356 Live/Registered
    Novo Nordisk A/S
    2013-10-25

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.